Laboratory and Clinical Outcomes for Patient 1 and 2 Through After CAR T-Cell Infusion
| Patient 1 | Patient 2 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Parameter, units [reference range] | Pre-LD | Day 0 | Day 14 | Day 28 | Day 56 | Day 90 | Pre-LD | Day 0 | Day 14 | Day 28 |
| CD19+ B cells, cells/µL [107–698] | 22 | 0 | 0 | 1 | 7 | 102 | 52 | 3 | 0 | 0 |
| ANC, ×109/L [1.80–7.00] | 4.5 | 0.5 | 3.7 | 3.6 | 3.8 | 4.7 | 3.8 | 1.7 | 1.1 | 6.2 |
| Hemoglobin, g/dL [11.5–15.5] | 12 | 9.1 | 9.5 | 11.7 | 12.6 | 12.9 | 9 | 7.9 | 9.2 | 9.3 |
| Platelets, ×109/L [150–400] | 93 | 54 | 78 | 103 | 175 | 201 | 341 | 213 | 245 | 453 |
| CRP, mg/L [0–10] | 83.3 | 67.5 | 4.8 | 2.8 | 11.8 | 9.7 | 10.9 | 7.6 | 6.4 | 5.4 |
| Anti-dsDNA, IU [<25 = Negative] | 297 | 294 | 356 | 304 | 216 | 241 | 293 | 432 | 386 | 281 |
| C3, mg/dL [83–193] | 54 | 59 | 65 | 94 | 135 | 146 | 62 | 58 | 82 | 100 |
| C4, mg/dL [15.0–57.0] | 9.2 | 13 | 18.7 | 28.8 | 44.2 | 41.6 | 4.9 | 5.3 | 9.7 | 12.8 |
| Proteinuria, [UPCR] | 1.4 | 1.5 | 0.6 | 0.9 | 0.5 | 0.5 | 1.3 | 1.9 | 1.2 | 0.6 |
| SLEDAI-2K | 19 | 22 | 14 | 13 | 8 | 8 | 12 | 8 | 16 | 10 |
| IgG, mg/dL [757–1941] | 620 | 546 | 452 | 429 | 291 | 287 | 1254 | 970 | 1017 | 873 |
| IgM, mg/dL [33–393] | 87 | 73 | 23 | 12 | 5 | 20 | 106 | 85 | 80 | 70 |
| IgA, mg/dL [87–534] | 118 | 113 | 62 | 46 | 37 | 37 | 370 | 307 | 275 | 190 |
ANC, absolute neutrophil count; C3, complement component 3; C4, complement component 4; CRP, C-reactive protein; dsDNA, double-stranded DNA; Ig, immunoglobulin; LD, lymphodepletion; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000; UPCR, urine protein creatinine ratio.